echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Microbiology News > Immunoblotting and Enzyme-Linked Immunosorbent Assay

    Immunoblotting and Enzyme-Linked Immunosorbent Assay

    • Last Update: 2021-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Immunoassay using antibodies bound to a solid phase was first described in 1954 when D. W. Talmage and coworkers used a crude form of radioimmunoassay (RIA) to estimate the total antibody content of serum (
    1
    ). Various technological developments, notably the coupling of enzymes to antibodies, allowed enzyme-linked immunosorbent assay (ELIBA) techniques as used today to be developed. A further major advance was the technique of transfer of proteins from electrophoretic gels to nitrocellulose sheets, and the subsequent probing of the sheets with antibodies—the Western blot, developed in its modern form by Towbin and coworkers in 1979 (
    2
    ).
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.